Results 141 to 150 of about 42,901 (212)

Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis. [PDF]

Cancer Cell
Dang D, Deogharkar A, McKolay J, Smith KS, Panwalkar P, Hoffman S, Tian W, Ji S, Azambuja AP, Natarajan SK, Lum J, Bayliss J, Manzeck K, Sweha SR, Hamanishi E, Pun M, Patel D, Rau S, Animasahun O, Achreja A, Ogrodzinski MP, Diessl J, Cotter J, Hawes D, Yang F, Doherty R, Franson AT, Hanaford AR, Eberhart CG, Raabe EH, Orr BA, Wechsler-Reya RJ, Chen B, Lyssiotis CA, Shah YM, Lunt SY, Banerjee R, Judkins AR, Prensner JR, Koschmann C, Waszak SM, Nagrath D, Simoes-Costa M, Northcott PA, Venneti S.   +44 more
europepmc   +1 more source

Isocitrate dehydrogenase of soybeans.

Indian journal of biochemistry & biophysics, 1975
R C, Gupta, R, Narayan
openaire   +1 more source

The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. [PDF]

Neuro Oncol
de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB, Young RJ, Huang RY, Ellingson BM, Capper D, Phillips JJ, Halasz LM, Shih HA, Rudà R, Lim-Fat MJ, Blumenthal DT, Weller M, Arakawa Y, Whittle JR, Ducray F, Reardon DA, Bi WL, Minniti G, Rahman R, Hervey-Jumper S, Chang SM, Wen PY.   +25 more
europepmc   +1 more source

Predicting isocitrate dehydrogenase status in glioma using hierarchical attention-based deep 3D multiple instance learning. [PDF]

Front Oncol
Xie Q, Sun Y, Liang Y, Shang Y, Wang H, Wang F, Wei R, Chen B, Zhang M, Niu C.   +9 more
europepmc   +1 more source

Phenotype augmentation using generative AI for isocitrate dehydrogenase mutation prediction in glioma. [PDF]

Sci Rep
Jung HK, Choi C, Park JE, Park SY, Lee JH, Kim N, Kim HS.   +6 more
europepmc   +1 more source

Improving radiomics-based isocitrate dehydrogenase 1 prediction in glioma patients using semi-supervised machine learning models. [PDF]

BMC Med Imaging
Ahmadzadeh AM, Jafarnezhad A, Elyassirad D, Vatanparast M, Gheiji B, Faghani S.   +5 more
europepmc   +1 more source

Leptomeningeal Enhancement Manifesting as a Treatment-Related Change in Isocitrate Dehydrogenase-Wildtype Glioblastoma Mimicking Leptomeningeal Metastases on Contrast-Enhanced FLAIR MRI: A Case Report. [PDF]

J Korean Soc Radiol
Kang JH, Kim M, Kim MS, Rho MH, Lee KH, Lee JJB.   +5 more
europepmc   +1 more source

Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma. [PDF]

Neurooncol Pract
Roth P, Capper D, Calabrese E, Halasz LM, Jakola AS.   +4 more
europepmc   +1 more source

Prognostic relevance of resection at first recurrence in isocitrate dehydrogenase mutant lower-grade glioma: results from a retrospective, single-center, volumetric analysis. [PDF]

J Neurooncol
Jungk C, Goepfert K, Gluszak M, Marhaba K, Dao Trong P, Krieg SM, Bendszus M, Sahm F, Unterberg AW.   +8 more
europepmc   +1 more source

Habitat subregions analysis based on neurite orientation dispersion and density imaging enhances isocitrate dehydrogenase genotyping in glioma. [PDF]

BMC Med Imaging
Yang Z, Lin R, Wu Z, Song Y, Yang G, Jiang R, Xue Y, Wáng YXJ.   +7 more
europepmc   +1 more source